Press Release
June 25 2026
- Patients complete SIBO breath testing at home, with diagnosis provided by an in-house OMED Health GI doctor and results returned to Welbeck’s clinicians via an online portal
- Home-based pathway widens patient access to SIBO testing, with doctor-reviewed diagnosis included and no added burden on referring clinicians
Cambridge and London, UK, June 25, 2026: OMED Health (“OMED”), part of Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, and Welbeck Health Partners (“Welbeck”), one of the UK’s largest specialist outpatient healthcare providers, today announced that Welbeck has adopted OMED Health’s home-based Small Intestinal Bacterial Overgrowth (SIBO) breath-testing pathway. The roll out across Welbeck’s network follows a three-month evaluation where the pathway was assessed for performance and impact on standard of care.
Under the pathway, a Welbeck clinician requests a SIBO test for a patient via the OMED clinical practitioner portal. Patients receive a home-testing kit containing the OMED Health Breath Analyzer, instructions for the companion app, and either a glucose or lactulose substrate1. The patient performs the breath test at home, and the results are delivered real-time and are reviewed and interpreted by an in-house OMED Health GI doctor to minimize the burden on the ordering clinician. The test results and diagnosis are returned to Welbeck’s clinicians through the practitioner portal for follow-up.
An estimated 17% of adults in the UK suffer from IBS symptoms2, which are often caused by SIBO3 or other gastrointestinal disorders. As a result, many patients experience prolonged delays in receiving an accurate diagnosis and appropriate treatment. Although SIBO can be treated through antibiotics, supplements, or dietary changes, access to diagnostic testing remains limited. By allowing SIBO testing to be completed at home, the OMED pathway is designed to improve access and convenience for Welbeck’s patients and to streamline the route from referral to result
Dr Devinder Bansi, Consultant Gastroenterologist and founding partner of Welbeck, said: “Home-based testing makes SIBO analysis much more accessible for our patients, many of whom would otherwise need to arrange a dedicated clinic visit. Additionally, having specialist diagnosis included as part of the service means our consultants can confidently follow up with their patients and expedite care. After working with the OMED pathway over the past few months, we were satisfied that it supports the quality and standard of care our patients expect from Welbeck and so have chosen to make it available more widely across our network.”
Billy Boyle, co-founder and CEO at Owlstone Medical, said: “Too many people living with debilitating digestive symptoms wait far longer than they should for diagnosis and a clear treatment plan. This partnership shows how that can change: through home-based SIBO testing, with expert diagnosis handled by our team, Welbeck is widening access to specialist digestive care without adding burden to busy referring clinicians. We are delighted to be working with Welbeck, and see this partnership as a model for making SIBO testing part of routine care.”
The OMED Health Breath Analyzer used in the pathway carries UKCA marking, and the service is delivered under Owlstone Medical’s Care Quality Commission (CQC) registration.
- https://omedhealth.com/sibo-test/
- https://www.bjmp.org/content/irritable-bowel-syndrome-primary-care-physicians
- https://pubmed.ncbi.nlm.nih.gov/31750966/
ENDS
Notes to Editors:
For more information please contact:
Dr Ben Rutter, Zyme Communications
ben.rutter@zymecommications.com
+44 (0) 7920-770935
To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please click here.
About Owlstone Medical:
Owlstone Medical’s vision is to save 100,000 lives by realizing the enormous promise of breath-based diagnostics through the development and application of Breath Biopsy®, a unique platform capable of both biomarker discovery and use in routine clinical testing. The platform includes the Breath Biopsy VOC Atlas, the most extensive catalogue of identified volatile organic compounds (VOCs) commonly found on breath. The Company’s technology is protected by over 160 granted and pending patents and has been used in more 100 research papers.
Owlstone Medical’s Research Products and Services are being deployed at over 100 sites around the world with large pharmaceutical companies and leading academic institutions, and the company has partnered with the Gates Foundation, the U.S. Department of Defense, the Cystic Fibrosis Foundation, and the FDA. Projects are supported by Breath Biopsy OMNI®, the most advanced solution for reliable end-to-end global breath VOC analysis, which is helping researchers advance biomarker discovery and disease research and maximizing the chances of finding clinically relevant breath biomarkers.
The Company has a portfolio of Breath Biopsy tests in development for the early detection of lung cancer and liver disease, both areas of high unmet clinical need that represent multi-billion dollar market opportunities. In digestive health, under the OMED Health brand, Owlstone has launched the OMED Health Breath Analyzer, and an associated app that allows for regular tracking of diet and lifestyle factors. In Great Britain, the OMED offer includes doctor-led OMED Health Plans, personalized treatments and services to help patients gain control of their functional gastrointestinal conditions.
About Welbeck Health Partners
Welbeck Health Partners is one of the UK’s largest specialist outpatient healthcare providers. Founded by a group of leading clinicians and healthcare specialists who believed care could be delivered in a more effective, patient-centred way, Welbeck partners with expert consultants to build bespoke centres of excellence spanning advanced diagnostics, the latest treatments, and minimally invasive day-case surgery. Since opening its flagship London centre in 2019, Welbeck has treated more than 100,000 patients and now brings together 21 specialist centres — including Digestive Health — under one roof, with new regional centres opening in Cambridge and Oxford in 2026. Welbeck is registered with the Care Quality Commission (CQC).
Looking to the Future of Gastroenterology
As Welbeck Health Partners continues its expansion, with new regional centres of excellence opening in Cambridge and Oxford in 2026, the adoption of the OMED Health pathway highlights a mutual commitment to scalable, patient-centred digital health solutions.
For healthcare practitioners interested in learning how to integrate the OMED Health SIBO testing pathway into their own practices, please visit our OMED Health Practitioner Page
